BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

897 related articles for article (PubMed ID: 20129068)

  • 1. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.
    Tiews S; Steinberg W; Schneider W; Hanrath C
    J Clin Virol; 2009 Nov; 46 Suppl 3():S11-5. PubMed ID: 20129068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
    Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
    J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
    Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
    BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.
    Şuteu O; Blaga ML; Nygård M; Leinonen MK; Nicula F; Păiş R; Coza D; Cadariu PA; Melnic A; Andreassen T; Hashim D; Weiderpass E
    Eur J Cancer Prev; 2020 Mar; 29(2):141-148. PubMed ID: 31033568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience of Combined Liquid Based Cervical Cytology and High-Risk HPV mRNA for Cervical Cancer Screening in Thammasat University Hospital.
    Muangto T; Chanthasenanont A; Lertvutivivat S; Nanthakomon T; Pongrojpaw D; Bhamarapravatana K; Suwannarurk K
    Asian Pac J Cancer Prev; 2016; 17(9):4409-4413. PubMed ID: 27797253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer.
    Gyllensten U; Sanner K; Gustavsson I; Lindell M; Wikström I; Wilander E
    Br J Cancer; 2011 Aug; 105(5):694-7. PubMed ID: 21811250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Previous Papanicolaou and Hybrid Capture 2 human papillomavirus testing results of 5699 women with histologically diagnosed cervical intraepithelial neoplasia 2/3.
    Wu T; Chen X; Zheng B; Li J; Xie F; Ding X; Zeng Z; Zhao C
    J Am Soc Cytopathol; 2019; 8(4):206-211. PubMed ID: 31272603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Performance of HPV E6/E7 mRNA and HPV DNA Assays for the Detection and Screening of Oncogenic Human Papillomavirus Infection among Woman with Cervical Lesions in China.
    Wang HY; Lee D; Park S; Kim G; Kim S; Han L; Yubo R; Li Y; Park KH; Lee H
    Asian Pac J Cancer Prev; 2015; 16(17):7633-40. PubMed ID: 26625774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
    Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
    Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
    Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
    Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytology versus HPV testing for cervical cancer screening in the general population.
    Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of high-risk HPV tests for primary cervical screening.
    Meijer CJ; Berkhof H; Heideman DA; Hesselink AT; Snijders PJ
    J Clin Virol; 2009 Nov; 46 Suppl 3():S1-4. PubMed ID: 20129067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [High-risk HPV genotyping PCR testing as a means of cervical cancer and precancerous lesions early screening].
    Ma L; Cong X; Bian M; Shi M; Wang X; Liu J; Liu H
    Zhonghua Fu Chan Ke Za Zhi; 2015 Apr; 50(4):246-52. PubMed ID: 26080934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population.
    Inoue M; Sakaguchi J; Sasagawa T; Tango M
    Int J Gynecol Cancer; 2006; 16(3):1007-13. PubMed ID: 16803477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
    Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
    J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland.
    Leinonen MK; Anttila A; Malila N; Dillner J; Forslund O; Nieminen P
    Br J Cancer; 2013 Nov; 109(11):2941-50. PubMed ID: 24136148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.
    Leinonen MK; Nieminen P; Lönnberg S; Malila N; Hakama M; Pokhrel A; Laurila P; Tarkkanen J; Anttila A
    BMJ; 2012 Nov; 345():e7789. PubMed ID: 23197596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
    Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
    Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.